Core Viewpoint - Nutanix reported quarterly earnings of $0.41 per share, matching the Zacks Consensus Estimate, but down from $0.42 per share a year ago [1] - The company posted revenues of $670.58 million for the quarter ended October 2025, missing the Zacks Consensus Estimate by 0.86%, but up from $590.96 million year-over-year [2] Financial Performance - Nutanix has surpassed consensus EPS estimates three times over the last four quarters [2] - The company had a surprise of +15.63% in the previous quarter, with actual earnings of $0.37 per share compared to an expected $0.32 [1][2] - The current consensus EPS estimate for the upcoming quarter is $0.54, with expected revenues of $748.98 million, and for the current fiscal year, the EPS estimate is $1.89 on revenues of $2.92 billion [7] Stock Performance - Nutanix shares have declined approximately 4.7% since the beginning of the year, contrasting with the S&P 500's gain of 14% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Outlook - The Computers - IT Services industry, to which Nutanix belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Nutanix's stock performance [5]

TWFG, Inc. (TWFG) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in ...

Wall Street analysts expect Kohl's (KSS) to post quarterly loss of -$0.19 per share in its upcoming report, which indicates a year-over-year decline of 195%. Revenues are expected to be $3.49 billion, down 5.9% from the year-ago quarter.The consensus EPS estimate for the quarter has been revised 15% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a company's earnings anno ...

Company Performance - Northern Technologies reported a quarterly loss of $0.06 per share, missing the Zacks Consensus Estimate of $0.08, compared to earnings of $0.20 per share a year ago, representing an earnings surprise of -175.00% [1] - The company posted revenues of $22.32 million for the quarter ended August 2025, missing the Zacks Consensus Estimate by 0.38%, and down from $23.35 million year-over-year [2] - Northern Technologies has not surpassed consensus EPS estimates over the last four quarters and has topped consensus revenue estimates only twice in that period [2] Stock Performance - Shares of Northern Technologies have declined approximately 41.1% since the beginning of the year, contrasting with the S&P 500's gain of 13.4% [3] - The current consensus EPS estimate for the upcoming quarter is $0.02 on revenues of $20.7 million, and for the current fiscal year, it is $0.28 on revenues of $89.1 million [7] Industry Outlook - The Zacks Industry Rank for Chemical - Diversified is currently in the bottom 9% of over 250 Zacks industries, indicating a challenging environment for the sector [8] - The performance of Northern Technologies may be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Viewpoint - Sera Prognostics, Inc. reported a quarterly loss of $0.16 per share, which was better than the Zacks Consensus Estimate of a loss of $0.19, indicating an earnings surprise of +15.79% [1] Group 1: Earnings Performance - The company has surpassed consensus EPS estimates three times over the last four quarters [2] - The quarterly revenue was $0.02 million, missing the Zacks Consensus Estimate by 75.39%, compared to $0.03 million in the same quarter last year [2] - The stock has lost approximately 61.7% since the beginning of the year, while the S&P 500 has gained 16.5% [3] Group 2: Future Outlook - The future performance of Sera Prognostics' stock will depend on management's commentary during the earnings call and the company's earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $0.1 million, and for the current fiscal year, it is -$0.73 on revenues of $0.12 million [7] Group 3: Industry Context - The Medical Services industry, to which Sera Prognostics belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, which may impact the stock's performance [8]

Core Viewpoint - Insulet (PODD) is experiencing solid improvement in earnings estimates, which is likely to positively impact its stock price momentum [1][2]. Earnings Estimate Revisions - The trend in estimate revisions reflects growing analyst optimism regarding Insulet's earnings prospects, which historically correlates with stock price movements [2]. - For the current quarter, Insulet is expected to earn $1.47 per share, representing a year-over-year increase of +27.8%. Over the last 30 days, seven estimates have been revised upward, leading to a 12.07% increase in the Zacks Consensus Estimate [6]. - For the full year, the earnings estimate stands at $4.89 per share, indicating a +50.9% change from the previous year. Eight estimates have moved higher in the past month, resulting in a 6.1% boost to the consensus estimate [7][8]. Zacks Rank and Performance - Insulet currently holds a Zacks Rank 1 (Strong Buy), supported by favorable estimate revisions. This ranking is associated with a strong historical performance, with Zacks 1 stocks averaging a +25% annual return since 2008 [3][9]. - The stock has gained 7.8% over the past four weeks, indicating investor confidence in its earnings growth prospects [10].

Core Viewpoint - Flutter Entertainment reported quarterly earnings of $1.64 per share, significantly exceeding the Zacks Consensus Estimate of $0.13 per share, marking an earnings surprise of +1,161.54% [1] - The company posted revenues of $3.79 billion for the quarter ended September 2025, which was below the Zacks Consensus Estimate by 1.65% [2] Financial Performance - Earnings per share (EPS) for the current quarter was $1.64, compared to $0.43 per share a year ago [1] - Revenue for the quarter was $3.79 billion, up from $3.25 billion year-over-year [2] - Over the last four quarters, Flutter has surpassed consensus EPS estimates four times and topped revenue estimates two times [2] Market Performance - Flutter shares have declined approximately 10.3% since the beginning of the year, while the S&P 500 has gained 16.4% [3] - The current Zacks Rank for Flutter is 4 (Sell), indicating expected underperformance in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is $2.73 on revenues of $5.37 billion, and for the current fiscal year, it is $8.08 on revenues of $17.06 billion [7] - The gaming industry is currently ranked in the bottom 39% of Zacks industries, which may impact Flutter's stock performance [8]

Core Insights - Bolt Biotherapeutics, Inc. reported a quarterly loss of $3.72 per share, which was better than the Zacks Consensus Estimate of a loss of $5.07, marking an earnings surprise of +26.63% [1] - The company generated revenues of $2.17 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 294.36% and showing an increase from $1.14 million in the same quarter last year [2] - The stock has underperformed, losing approximately 55.1% since the beginning of the year, while the S&P 500 has gained 16.4% [3] Financial Performance - Over the last four quarters, Bolt Biotherapeutics has surpassed consensus EPS estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$4.85 on revenues of $0.5 million, and for the current fiscal year, it is -$20.72 on revenues of $4.07 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Bolt Biotherapeutics belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - Plug Power (PLUG.US), a leading provider of hydrogen economy solutions, is set to announce its Q3 2025 earnings on November 10, with expectations of a wider loss and slight revenue decline compared to the previous year [1] Financial Performance Expectations - The market predicts a Q3 loss per share of $0.13, which represents a 48% increase in losses year-over-year [1] - Revenue is expected to be $170.02 million, reflecting a 2.1% decline compared to the same quarter last year [1] - Over the past 30 days, analysts have collectively raised their earnings expectations by 2%, indicating a positive adjustment trend [1] Business Segment Insights - Analysts forecast "net revenue (equipment, related infrastructure, and others)" to reach $98.03 million, down 8.5% year-over-year [1] - "Fuel cell systems and related infrastructure services net revenue" is expected to be $15.47 million, up 9.3% from the previous year [1] - "Power purchase agreement net revenue" is projected at $21.20 million, a 3.6% increase year-over-year [1] - "Net revenue (including fuel and related equipment delivered to customers)" is anticipated to be $32.53 million, reflecting a 9.2% growth compared to last year [1] Profitability Metrics - The expected gross profit for "fuel cell systems and related infrastructure services" is only $160,000, a significant decrease from $5.06 million in the same quarter last year [2]

Core Insights - CervoMed Inc. reported a quarterly loss of $0.84 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.68, and a decline from a loss of $0.55 per share a year ago, indicating a significant earnings surprise of -23.53% [1] - The company generated revenues of $0.32 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 69.24%, and a decrease from $1.94 million in the same quarter last year [2] - CervoMed Inc. shares have increased approximately 211.5% year-to-date, significantly outperforming the S&P 500's gain of 14.3% [3] Financial Performance - Over the last four quarters, CervoMed has surpassed consensus EPS estimates only once, while it has topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.65 on revenues of $0.9 million, and for the current fiscal year, it is -$2.58 on revenues of $5.12 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which CervoMed belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]